Colorectal Cancer
Conditions
Brief summary
The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects. The purpose of the Phase II portion is to find out how safe the study drug is when taken at the highest dose in a larger group of subjects.
Detailed description
The primary purpose for Phase 1b: to determine the maximum tolerated dose (MTD) of E7820 recommended for Phase 2 when administered in combination with the FOLFIRI regimen (irinotecan, leucovorin, and 5-fluorouracil \[5-FU\]) in participants with locally advanced or metastatic colorectal cancer (mCRC) who have failed first-line therapy. Phase 2: to evaluate the safety and tolerability of E7820 administered in combination with the FOLFIRI regimen, compared with FOLFIRI alone and FOLFIRI plus bevacizumab, in patients with locally advanced or mCRC who have failed first-line therapy.
Interventions
DRUGFOLFIRI
FOLFIRI will be administered as IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m\^2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump. The 5-FU IV bolus (400 mg/m\^2) and CIV infusion (2400 mg/m\^2) over 46 hours is repeated on Days 15 and 16 of each cycle.
DRUGE7820
E7820 will be administered orally in tablet form once daily, every day of each 28-day treatment cycle.
DRUGBevacizumab
Bevacizumab will be administered at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle.
Sponsors
Quintiles, Inc.
Eisai Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients may be entered in the study only if they meet all of the following criteria: 1. Male or female patient greater than or equal to 18 years of age; 2. Histologically or cytologically confirmed nonresectable locally advanced or metastatic colorectal adenocarcinoma; 3. Patients must have failed a first-line chemotherapy regimen for nonresectable locally advanced or mCRC (first-line bevacizumab is allowed). Patients randomized to the Phase Ib portion can have up to 3 total prior regimens (including adjuvant therapy in addition to treatment for advanced disease); 4. At least 1 site of measurable disease by the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) criteria; 5. Life expectancy of \> 3 months; 6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1; 7. Patients must have adequate renal function as evidenced by serum creatinine \<2 mg/dL and creatinine clearance \>50 mL/minute per the Cockcroft and Gault formula; 8. Patients must have adequate bone marrow function as evidenced by absolute neutrophil count (ANC) \>1.5 x 109/L, platelets \>100 x 109/L, hemoglobin \>9.0 g/dL (a hemoglobin \<9.0 g/dL at Screening is acceptable if it is corrected to \>9 g/dL by growth factor or transfusion prior to first dose); 9. Patients must have adequate liver function as evidenced by bilirubin \<1.5 times the upper limit of the normal range (ULN), and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) \<3 X ULN (in the case of liver metastases, \<5 X ULN). If there are bone metastases, liver-specific alkaline phosphatase may be separated from the total and used to assess liver function instead of total alkaline phosphatase; 10. Blood pressure must be well-controlled (\<140/90 mmHg at screening) with or without antihypertensive medication. Patients must have no history of hypertensive crisis or hypertensive encephalopathy; 11. Male or female patients of child-producing potential must agree to use double barrier contraception, oral contraceptives, or avoidance of pregnancy measures during the study and for 90 days after the last day of treatment; 12. Females of childbearing potential must have a negative serum pregnancy test; 13. Females may not be breastfeeding; and 14. Ability to understand and willingness to sign a written consent.
Exclusion criteria
Patients will not be entered in the study for any of the following reasons: 1. Received chemotherapy, targeted therapy, radiotherapy, surgery, immunotherapy, or treatment in another clinical study within the 30 days prior to commencing study treatment or have not recovered from side effects of all treatment-related toxicities to Grade \<1, except for peripheral neuropathy (Grade 1 and Grade 2 are permitted) and alopecia; 2. Previously received irinotecan or irinotecan derivatives; 3. Previously received anti-alpha 2 integrin therapy; 4. History of other malignancies except: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated, a) in situ carcinoma of the uterine cervix, b) prostate cancer, or c) superficial bladder cancer; or (3) other curatively treated solid tumor with no evidence of disease for \>5 years; 5. Presence of brain metastases, unless the patient has received adequate treatment at least 4 weeks prior to randomization, and is stable, asymptomatic, and off steroids for at least 4 weeks prior to randomization; 6. Are currently receiving any other anticancer treatment; 7. Palliative radiotherapy is not permitted throughout the study period; 8. Serious non-healing wound, ulcer, or active bone fracture; 9. Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for a major surgical procedure during the course of the study; 10. Refractory nausea and vomiting, malabsorption, significant bowel resection, or any other medical condition that would preclude adequate absorption or result in the inability to take oral medication; 11. Significant cardiovascular impairment (history of congestive heart failure New York Heart Association \[NYHA\] Grade \>2, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia); 12. Active hemoptysis (defined as bright red blood of 13. Current or recent use (within 7 days) of full-dose warfarin (except low-dose warfarin as required to maintain patency of preexisting, permanent indwelling IV catheters). For subjects receiving warfarin, International Normalization Ratio (INR) should be \<1.5. Patients may have prophylactic use of low molecular weight heparin, however therapeutic use of heparin or low molecular weight heparin is not acceptable; 14. History of bleeding diathesis or coagulopathy; 15. Any history of cerebral vascular accident, transient ischemic attack or ≥ Grade 2 peripheral vascular disease, unless they have had no evidence of active disease for at least 6 months prior to randomization; 16. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1, unless affected area has been removed surgically; 17. Patients with organ allografts requiring immunosuppression; 18. Known positive human immunodeficiency virus (HIV), known hepatitis B surface antigen, or active hepatitis C positive; 19. Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, irinotecan, 5-FU, or leucovorin; 20. Hypersensitivity to sulfonamide derivatives; or 21. Have any medical condition that would interfere with the conduct of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECGs) Parameter | From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months) | ECG was to be a complete standardized 12-lead recording. The ECGs were reviewed by the investigator or designee prior to study drug administration as part of the participant's standard of care. |
| Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) | Cycle 1 (each cycle length=28 days) | Dose-limiting toxicities were defined as clinically significant adverse events (AEs) occurring less than or equal to (\<=) 28 days after commencing study treatment and considered by the investigator to be possibly or probably related to study treatment. Toxicity was evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v.4.0). |
| Phase 1b: Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) | From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months) | Adverse Events were defined as TEAEs if they started on or after the date and time of administration of the first dose of study drug during the study. An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, and which did not necessarily have a causal relationship with this treatment. Any change in hematology, clinical chemistry, urine values and regular measurement of vital signs which were deemed clinically significant by the investigator were recorded as TEAE. |
| Phase 1b: Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG-PS) | From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months) | ECOG-PS measured participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (greater than\[ \>\] 50 percent \[%\] of waking hours), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair \>50% of waking hours; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead. |
| Phase 1b: Number of Participants With Clinically Significant Changes in Physical Examinations | From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months) | Physical examination included examination of the head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, lymph nodes, and neurological status. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase 2: Time to Progression (TTP) | From date randomization to date of PD or death, up to 11 months | TTP was defined as time from the date of randomization of a participant until the date of first documented progression of such participant's disease based on investigator assessments according to RECIST v.1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. |
| Phase 2: Objective Response Rate (ORR) | From date of treatment start to until date of first PD or death (whichever occurred first), up to 11 months | ORR was defined as percentage of participants in the study whose best overall response was either CR or PR based on investigator assessments according to RECIST v1.1. A confirmatory scan was required after no less than 4 weeks and no later than 8 weeks, starting on the date that the response was first recorded. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<)10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
| Phase 2: Overall Survival (OS) | From date of randomization to date of PD or death, up to 11 months | OS was defined as time from the date of randomization of a participant until the date of death of such participant, regardless of the actual cause of the participant's death. |
| Phase 2: Progression-Free Survival (PFS) | From the date of randomization to date of PD or death (whichever occurred first), up to 11 months | PFS was defined as the time from the date of randomization of a participant to the date of first documentation of PD or death (whichever occurred first) based on investigator assessments according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. PD was defined as at least a 20% increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. |
Countries
Australia, India, Russia, Ukraine, United States
Participant flow
Recruitment details
Participants took part in the study at 4 investigative sites in Australia and the United States from 04 March 2010 to 18 February 2011.
Pre-assignment details
A total of 5 participants were enrolled and treated in Phase 1b part of the study and only safety was analyzed for all participants in this study. The planned dose escalation of E7820 at 70 milligram per day (mg/day), 100 mg/day and Phase 2 part were not conducted as the study was terminated early without determination of the Maximum Tolerated Dose (MTD) as the combination of E7820 plus FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil \[5-FU\]) was deemed to be not tolerable.
Participants by arm
| Arm | Count |
|---|---|
| Phase 1b: E7820 40 mg/Day + FOLFIRI Participants received E7820 40 mg/day tablets orally, in combination with a FOLFIRI regimen on Days 1 to 2 and 15 to 16 of each 28-day treatment cycle. FOLFIRI regimen consisted of; Irinotecan 180 mg/m\^2, Leucovorin 200 mg/m\^2 administered by IV infusion on Days 1 and 15 of each 28-day treatment cycle, and 400 mg/m\^2 5 -FU administered as an IV bolus injection followed by a total of 2400 mg/m\^2 5-FU administered by CIV infusion over 46 hours on Days 1 to 2, then repeated on Days 15 to 16 of each 28-day treatment cycle. Participants continued to receive study treatment unless there was occurrence of PD, unacceptable toxicity, withdrawal of consent, withdrawal by the investigator, lost to follow-up, or death, whichever occurred first. | 5 |
| Total | 5 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Phase 1b (Dose Escalation Phase) | Adverse Event | 1 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b (Dose Escalation Phase) | Physician Decision | 1 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b (Dose Escalation Phase) | Progression of disease | 1 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b (Dose Escalation Phase) | Withdrawal by Subject | 1 | 0 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Phase 1b: E7820 40 mg/Day + FOLFIRI |
|---|---|
| Age, Customized 43 - 83 years | 5 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 5 Participants |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 2 / 5 |
| other Total, other adverse events | 5 / 5 |
| serious Total, serious adverse events | 2 / 5 |
Outcome results
Primary
Phase 1b: Number of Participants With Any Treatment-emergent Adverse Events (TEAEs)
Adverse Events were defined as TEAEs if they started on or after the date and time of administration of the first dose of study drug during the study. An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, and which did not necessarily have a causal relationship with this treatment. Any change in hematology, clinical chemistry, urine values and regular measurement of vital signs which were deemed clinically significant by the investigator were recorded as TEAE.
Time frame: From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months)
Population: Safety population included all participants who received at least one dose of study drug and who had safety assessment post the first dose.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b: E7820 40 mg/Day + FOLFIRI | Phase 1b: Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) | 5 Participants |
Primary
Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECGs) Parameter
ECG was to be a complete standardized 12-lead recording. The ECGs were reviewed by the investigator or designee prior to study drug administration as part of the participant's standard of care.
Time frame: From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months)
Population: Safety population included all participants who received at least one dose of study drug and who had safety assessment post the first dose.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b: E7820 40 mg/Day + FOLFIRI | Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECGs) Parameter | 1 Participants |
Primary
Phase 1b: Number of Participants With Clinically Significant Changes in Physical Examinations
Physical examination included examination of the head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, lymph nodes, and neurological status.
Time frame: From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months)
Population: Safety population included all participants who received at least one dose of study drug and who had safety assessment post the first dose.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b: E7820 40 mg/Day + FOLFIRI | Phase 1b: Number of Participants With Clinically Significant Changes in Physical Examinations | 2 Participants |
Primary
Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)
Dose-limiting toxicities were defined as clinically significant adverse events (AEs) occurring less than or equal to (\<=) 28 days after commencing study treatment and considered by the investigator to be possibly or probably related to study treatment. Toxicity was evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v.4.0).
Time frame: Cycle 1 (each cycle length=28 days)
Population: Safety population included all participants who received at least one dose of study drug and who had safety assessment post the first dose.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b: E7820 40 mg/Day + FOLFIRI | Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) | 2 Participants |
Primary
Phase 1b: Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG-PS)
ECOG-PS measured participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (greater than\[ \>\] 50 percent \[%\] of waking hours), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair \>50% of waking hours; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead.
Time frame: From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months)
Population: Safety population included all participants who received at least one dose of study drug and who had safety assessment post the first dose.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1b: E7820 40 mg/Day + FOLFIRI | Phase 1b: Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG-PS) | Participants With ECOG-PS Grade 5 | 0 Participants |
| Phase 1b: E7820 40 mg/Day + FOLFIRI | Phase 1b: Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG-PS) | Participants With ECOG-PS Grade 1 | 1 Participants |
| Phase 1b: E7820 40 mg/Day + FOLFIRI | Phase 1b: Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG-PS) | Participants With ECOG-PS Grade 2 | 2 Participants |
| Phase 1b: E7820 40 mg/Day + FOLFIRI | Phase 1b: Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG-PS) | Participants With ECOG-PS Grade 3 | 2 Participants |
| Phase 1b: E7820 40 mg/Day + FOLFIRI | Phase 1b: Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG-PS) | Participants With ECOG-PS Grade 4 | 0 Participants |
Secondary
Phase 2: Objective Response Rate (ORR)
ORR was defined as percentage of participants in the study whose best overall response was either CR or PR based on investigator assessments according to RECIST v1.1. A confirmatory scan was required after no less than 4 weeks and no later than 8 weeks, starting on the date that the response was first recorded. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<)10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of treatment start to until date of first PD or death (whichever occurred first), up to 11 months
Population: The study was terminated before the initiation of Phase 2, so the data for this outcome measure was not collected and analyzed.
Secondary
Phase 2: Overall Survival (OS)
OS was defined as time from the date of randomization of a participant until the date of death of such participant, regardless of the actual cause of the participant's death.
Time frame: From date of randomization to date of PD or death, up to 11 months
Population: The study was terminated before the initiation of Phase 2, so the data for this outcome measure was not collected and analyzed.
Secondary
Phase 2: Progression-Free Survival (PFS)
PFS was defined as the time from the date of randomization of a participant to the date of first documentation of PD or death (whichever occurred first) based on investigator assessments according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. PD was defined as at least a 20% increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions.
Time frame: From the date of randomization to date of PD or death (whichever occurred first), up to 11 months
Population: The study was terminated before the initiation of Phase 2, so the data for this outcome measure was not collected and analyzed.
Secondary
Phase 2: Time to Progression (TTP)
TTP was defined as time from the date of randomization of a participant until the date of first documented progression of such participant's disease based on investigator assessments according to RECIST v.1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions.
Time frame: From date randomization to date of PD or death, up to 11 months
Population: The study was terminated before the initiation of Phase 2, so the data for this outcome measure was not collected and analyzed.